Document Detail

Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line devoid of caveolin-1.
MedLine Citation:
PMID:  21449981     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: N-acyl ethanolamines (NAEs) and 2-arachidonoyl glycerol (2-AG) are endogenous cannabinoids and along with related lipids are synthesized on demand from membrane phospholipids. Here, we have studied the compartmentalization of NAEs and 2-AG into lipid raft fractions isolated from the caveolin-1-lacking microglial cell line BV-2, following vehicle or cannabidiol (CBD) treatment. Results were compared with those from the caveolin-1-positive F-11 cell line.
EXPERIMENTAL APPROACH: BV-2 cells were incubated with CBD or vehicle. Cells were fractionated using a detergent-free continuous OptiPrep density gradient. Lipids in fractions were quantified using HPLC/MS/MS. Proteins were measured using Western blot.
KEY RESULTS: BV-2 cells were devoid of caveolin-1. Lipid rafts were isolated from BV-2 cells as confirmed by co-localization with flotillin-1 and sphingomyelin. Small amounts of cannabinoid CB(1) receptors were found in lipid raft fractions. After incubation with CBD, levels and distribution in lipid rafts of 2-AG, N-arachidonoyl ethanolamine (AEA), and N-oleoyl ethanolamine (OEA) were not changed. Conversely, the levels of the saturated N-stearoyl ethanolamine (SEA) and N-palmitoyl ethanolamine (PEA) were elevated in lipid raft fractions. In whole cells with growth medium, CBD treatment increased AEA and OEA time-dependently, while levels of 2-AG, PEA and SEA did not change.
CONCLUSIONS AND IMPLICATIONS: Whereas levels of 2-AG were not affected by CBD treatment, the distribution and levels of NAEs showed significant changes. Among the NAEs, the degree of acyl chain saturation predicted the compartmentalization after CBD treatment suggesting a shift in cell signalling activity.
LINKED ARTICLES: This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit To view Part I of Cannabinoids in Biology and Medicine visit
Neta Rimmerman; Heather B Bradshaw; Ewa Kozela; Rivka Levy; Ana Juknat; Zvi Vogel
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  165     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-26     Completed Date:  2012-07-27     Revised Date:  2014-08-21    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  2436-49     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cannabidiol / pharmacology*
Cannabinoid Receptor Modulators / metabolism*
Caveolin 1 / deficiency
Cell Line
Membrane Microdomains / metabolism*
Microglia / metabolism
Receptor, Cannabinoid, CB1 / metabolism
Receptor, Cannabinoid, CB2 / metabolism
Grant Support
Reg. No./Substance:
0/Cannabinoid Receptor Modulators; 0/Caveolin 1; 0/Cnr2 protein, mouse; 0/Endocannabinoids; 0/Receptor, Cannabinoid, CB1; 0/Receptor, Cannabinoid, CB2; 19GBJ60SN5/Cannabidiol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates mult...
Next Document:  A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell dea...